Illumina Inc (ILMN) Stock AnalysisILMNIllumina Inc

Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Illumina Inc is currently trading at $262.54, which is above the analyst price targets from BofA ($168) and Barclays ($200), but below the targets from RBC Capital ($310), Guggenheim ($305), and Leerink ($300). The RSI is at 39.288, indicating the stock is nearing oversold conditions, but the recent insider selling has increased by 17343.19%, which raises concerns about confidence in the stock. Given these mixed signals, it is advisable to hold rather than buy at this moment.

18 analysts cover ILMN: 11 rate it Buy, 6 Hold and 1 Sell. The average price target is 133.54.